Stockscreener 앱 받기
4.29
3.37%
0.14
시간 외 거래:
4.42
0.13
+3.03%
Verastem Inc 주식(VSTM)의 최신 뉴스
Verastem’s SWOT analysis: biotech stock poised for growth amid challenges By Investing.com - Investing.com South Africa
Verastem’s SWOT analysis: biotech stock poised for growth amid challenges - Investing.com
(VSTM) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Verastem Announces Positive Data From Cancer Trial Conducted By Partner: Retail Turns Bullish - MSN
ASCO 2025: Verastem has positive cancer data but stock sags - BioWorld MedTech
Cantor Fitzgerald reiterates overweight rating on Verastem stock By Investing.com - Investing.com Nigeria
Transcript : Verastem, Inc.Special Call - marketscreener.com
What's Going On With Verastem Oncology Stock On Monday? - Benzinga
Verastem Oncology Announces Updated Data from Partner GenFleet T - GuruFocus
Verastem (VSTM) Reports Promising Results in GFH375 Trial for Ca - GuruFocus
Verastem (VSTM) Reports Promising Results in GFH375 Trial for Cancer Treatment | VSTM Stock News - GuruFocus
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor - BioSpace
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor | VSTM Stock News - GuruFocus
Verastem reports promising cancer drug trial results By Investing.com - Investing.com Nigeria
(VSTM) Proactive Strategies - news.stocktradersdaily.com
VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval - sharewise
Verastem Oncology to Present at the Jefferies Global Healthcare Conference | VSTM Stock News - GuruFocus
Verastem Oncology to Present at the Jefferies Global Healthcare Conference - Business Wire
Verastem stock soars to 52-week high, hits $8.5 By Investing.com - Investing.com South Africa
Verastem stock soars to 52-week high, hits $8.5 - Investing.com Australia
US High Growth Tech Stocks to Watch in May 2025 - simplywall.st
VSTM Up As NDA For Ovarian Cancer Combo Gets FDA's Priority Review Tag - Barchart.com
Analysts Are Bullish on These Healthcare Stocks: Verastem (VSTM), Kazia Therapeutics (KZIA) - The Globe and Mail
Verastem (VSTM) Stock Price, News & Analysis - MarketBeat
Verastem announces positive Phase 1/2 safety and efficacy results in PDAC - Yahoo Finance
Verastem Announces Positive RAMP 205 Trial Results - TipRanks
Verastem Oncology Announces Positive Updated Results from RAMP 2 - GuruFocus
Verastem (VSTM) Reports Promising Results in Metastatic Pancreatic Cancer Trial | VSTM Stock News - GuruFocus
Verastem Says Pancreatic Cancer Patients in Phase 1/2 Trial of Avmapki Achieve 83% Overall Response Rate - marketscreener.com
Verastem Oncology reports high response in pancreatic cancer trial By Investing.com - Investing.com Canada
Verastem Oncology reports high response in pancreatic cancer trial - Investing.com
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma - FinancialContent
Verastem’s SWOT analysis: biotech firm’s stock poised for growth amid challenges - Investing.com
Verastem Inc (VSTM) Has Recovered 72.4% From Its Low: Is This The Beginning Of A Trend? - Stocksregister
Verastem CFO sells $90,592 in stock By Investing.com - Investing.com UK
Tempus and Verastem partner on ovarian cancer diagnostic test By Investing.com - Investing.com South Africa
Verastem CFO sells $90,592 in stock - Investing.com
Tempus partners with Verastem for companion diagnostic development - Yahoo Finance
Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment - 01net
Tempus AI, Inc. Announces Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment - marketscreener.com
Tempus AI teams up with Verastem for companion diagnostic test - Seeking Alpha
Tempus and Verastem partner on ovarian cancer diagnostic test - Investing.com Australia
Breakthrough: Tempus Partners on First-Ever FDA-Approved Test for KRAS-Mutant Ovarian Cancer Treatment - Stock Titan
The Manufacturers Life Insurance Company Makes New $74,000 Investment in Verastem, Inc. (NASDAQ:VSTM) - Defense World
(VSTM) Investment Analysis - news.stocktradersdaily.com
Tower Research Capital LLC TRC Grows Holdings in Verastem, Inc. (NASDAQ:VSTM) - Defense World
Stifel Financial Corp Grows Stake in Verastem, Inc. (NASDAQ:VSTM) - Defense World
11,402 Shares in Verastem, Inc. (NASDAQ:VSTM) Purchased by Voya Investment Management LLC - Defense World
Verastem (VSTM) Plans to Offer 3.43 Million Shares of Common Sto - GuruFocus
0.39%
0.42%
자본화:
|
볼륨(24시간):